The Prognosis Of Peroxiredoxin Family In Breast Cancer

References

• Chae HZ, Oubrahim H, Park JW, Rhee SG, Chock PB. Protein glutathionylation in the regulation of peroxiredoxins: a family of thiol-specific peroxidases that function as antioxidants, molecular chaperones, and signal modulators. Antioxid Redox Signal. 2012;16(6):506–523. doi:10.1089/ars.2011.426022114845
   PubMed Web of Science ®Google Scholar
• Immenschuh S, Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal. 2005;7(5–6):768–777. doi:10.1089/ars.2005.7.76815890023
   PubMed Web of Science ®Google Scholar
• Lu W, Fu Z, Wang H, Feng J, Wei J, Guo J. Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress. Mol Cell Biochem. 2014;387(1–2):261–270. doi:10.1007/s11010-013-1891-424234423
   PubMed Web of Science ®Google Scholar
• Lu W, Fu Z, Wang H, Feng J, Wei J, Guo J. Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/beta-catenin signaling. Cancer Lett. 2014;343(2):190–199. doi:10.1016/j.canlet.2013.10.00224125860
   PubMed Web of Science ®Google Scholar
• Song IS, Jeong YJ, Jeong SH, et al. FOXM1-induced PRX3 regulates stemness and survival of colon cancer cells via maintenance of mitochondrial function. Gastroenterology. 2015;149(4):1006–1016 e1009. doi:10.1053/j.gastro.2015.06.00726091938
   PubMed Web of Science ®Google Scholar
• Guo X, Noguchi H, Ishii N, et al. The association of peroxiredoxin 4 with the initiation and progression of hepatocellular carcinoma. Antioxid Redox Signal. 2019;30(10):1271–1284. doi:10.1089/ars.2017.742629687726
   PubMed Web of Science ®Google Scholar
• Fang Y, He J, Janssen HLA, Wu J, Dong L, Shen XZ. Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence. J Dig Dis. 2018;19(3):155–169. doi:10.1111/1751-2980.1258029377617
   PubMed Web of Science ®Google Scholar
• Sun QK, Zhu JY, Wang W, et al. Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Med Oncol. 2014;31(1):786. doi:10.1007/s12032-013-0786-224297309
   PubMed Web of Science ®Google Scholar
• Chung KH, Lee DH, Kim Y, et al. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 2010;9(1):451–457. doi:10.1021/pr900811x19902980
   PubMed Web of Science ®Google Scholar
• Wang XY, Wang HJ, Li XQ. Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumour Biol. 2013;34(4):2275–2281. doi:10.1007/s13277-013-0769-023564483
   PubMedGoogle Scholar
• Jo M, Yun HM, Park KR, et al. Lung tumor growth-promoting function of peroxiredoxin 6. Free Radic Biol Med. 2013;61:453–463. doi:10.1016/j.freeradbiomed.2013.04.03223643677
   PubMed Web of Science ®Google Scholar
• Soini Y, Kinnula VL. High association of peroxiredoxins with lung cancer. Lung Cancer. 2012;78(2):167. doi:10.1016/j.lungcan.2012.08.01322981900
   PubMed Web of Science ®Google Scholar
• Wei Q, Jiang H, Xiao Z, et al. Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci U S A. 2011;108(17):7004–7009. doi:10.1073/pnas.101301210821487000
   PubMed Web of Science ®Google Scholar
• Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13(13):3875–3882. doi:10.1158/1078-0432.CCR-06-289317606720
   PubMed Web of Science ®Google Scholar
• Jiang H, Wu L, Mishra M, Chawsheen HA, Wei Q. Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy. Am J Cancer Res. 2014;4(5):445–460.25232487
   PubMed Web of Science ®Google Scholar
• Deighton RF, Le Bihan T, Martin SF, et al. Interactions among mitochondrial proteins altered in glioblastoma. J Neurooncol. 2014;118(2):247–256. doi:10.1007/s11060-014-1430-524728830
   PubMed Web of Science ®Google Scholar
• Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007;98(2):201–213. doi:10.1111/j.1349-7006.2007.00374.x17233837
   PubMed Web of Science ®Google Scholar
• Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res. 2011;71(5):1637–1646. doi:10.1158/0008-5472.CAN-10-367421343392
   PubMed Web of Science ®Google Scholar
• Ummanni R, Barreto F, Venz S, et al. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res. 2012;11(4):2452–2466. doi:10.1021/pr201172n22424448
   PubMed Web of Science ®Google Scholar
• Gong F, Hou G, Liu H, Zhang M. Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. Med Oncol. 2015;32(2):455. doi:10.1007/s12032-014-0455-025579166
   PubMed Web of Science ®Google Scholar
• Jiang L, Ren J, Xiao X, et al. Proteomic analysis of bladder cancer by iTRAQ after Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013;394(10):1333–1342. doi:10.1515/hsz-2013-020123893687
   PubMed Web of Science ®Google Scholar
• Taniuchi K, Furihata M, Hanazaki K, et al. Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity. Pancreas. 2015;44(2):331–340. doi:10.1097/MPA.000000000000027025426613
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. doi:10.1016/S0140-6736(16)31891-827865536
   PubMed Web of Science ®Google Scholar
• Fiskus W, Coothankandaswamy V, Chen J, et al. SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents. Cancer Res. 2016;76(18):5467–5478. doi:10.1158/0008-5472.CAN-16-012627503926
   PubMed Web of Science ®Google Scholar
• Desmetz C, Bascoul-Mollevi C, Rochaix P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res. 2009;15(14):4733–4741. doi:10.1158/1078-0432.CCR-08-330719584157
   PubMed Web of Science ®Google Scholar
• Luthra S, Chandran U, Diergaarde B, Becich M, Lee AV, Neumann CA. Expression of reactive species related genes is associated with patient survival in luminal B breast cancer. Free Radic Biol Med. 2018;120:170–180. doi:10.1016/j.freeradbiomed.2018.03.01129545070
   PubMed Web of Science ®Google Scholar
• Rafiei S, Tiedemann K, Tabaries S, Siegel PM, Komarova SV. Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis. Cancer Lett. 2015;361(2):262–270. doi:10.1016/j.canlet.2015.03.01225779674
   PubMedGoogle Scholar
• Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res. 2007;9(6):R76. doi:10.1186/bcr178917980029
   PubMed Web of Science ®Google Scholar
• Oncomine. Availalble from: https://www.oncomine.org/. Accessed 117, 2019.
   Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx24728407145
   PubMed Web of Science ®Google Scholar
• Kaplan Meier-plotter. Availalble from: https://kmplot.com/analysis/. Accessed 117, 2019.
   Google Scholar
• Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-920020197
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature1141223000897
   PubMed Web of Science ®Google Scholar
• cBioPortal for cancer genomics. Availalble from: https://www.cbioportal.org/. Accessed 117, 2019.
   Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-630944313
   PubMed Web of Science ®Google Scholar
• Metascape. Availalble from: http://www.metascape.org/.
   Google Scholar
• STRING: functional protein association networks. Availalble from: https://string-db.org/. Accessed 117, 2019.
   Google Scholar
• Cytoscape: an open source platform for complex network analysis and visualization. Availalble from: https://cytoscape.org/. Accessed 117, 2019.
   Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.21119131956
   PubMed Web of Science ®Google Scholar
• DAVID functional annotation bioinformatics microarray analysis. Availalble from: https://david.ncifcrf.gov/. Accessed 117, 2019.
   Google Scholar
• Zhao H, Langerod A, Ji Y, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004;15(6):2523–2536. doi:10.1091/mbc.e03-11-078615034139
   PubMed Web of Science ®Google Scholar
• Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11(1):R7. doi:10.1186/bcr222219187537
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352. doi:10.1038/nature1098322522925
   PubMed Web of Science ®Google Scholar
• Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518–527. doi:10.1038/nm176418438415
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi:10.1073/pnas.19136709811553815
   PubMed Web of Science ®Google Scholar
• Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–132. doi:10.1016/j.ccr.2006.01.01316473279
   PubMed Web of Science ®Google Scholar
• GEPIA (Gene Expression Profiling Interactive Analysis). Availalble from: http://gepia.cancer-pku.cn/. Accessed 117, 2019.
   Google Scholar
• van de Moosdijk AA, van Amerongen R. Identification of reliable reference genes for qRT-PCR studies of the developing mouse mammary gland. Sci Rep. 2016;6:35595. doi:10.1038/srep3559527752147
   PubMed Web of Science ®Google Scholar
• Wang X, He S, Sun JM, Delcuve GP, Davie JR. Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells. Mol Biol Cell. 2010;21(17):2987–2995. doi:10.1091/mbc.e10-02-016020631257
   PubMed Web of Science ®Google Scholar
• Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res. 2009;28:93. doi:10.1186/1756-9966-28-9319566940
   PubMed Web of Science ®Google Scholar
• Woolston CM, Storr SJ, Ellis IO, Morgan DAL, Martin SG. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. Radiother Oncol. 2011;100(2):308–313. doi:10.1016/j.radonc.2011.05.02921641069
   PubMed Web of Science ®Google Scholar
• O’Leary PC, Terrile M, Bajor M, et al. Peroxiredoxin-1 protects estrogen receptor alpha from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Res. 2014;16(4):R79. doi:10.1186/bcr369125011585
   PubMed Web of Science ®Google Scholar
• Bajor M, Zych AO, Graczyk-Jarzynka A, et al. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer. 2018;119(7):873–884. doi:10.1038/s41416-018-0263-y30287919
   PubMed Web of Science ®Google Scholar
• Coumans JV, Gau D, Poljak A, Wasinger V, Roy P, Moens PD. Profilin-1 overexpression in MDA-MB-231 breast cancer cells is associated with alterations in proteomics biomarkers of cell proliferation, survival, and motility as revealed by global proteomics analyses. OMICS. 2014;18(12):778–791. doi:10.1089/omi.2014.007525454514
   PubMed Web of Science ®Google Scholar
• Turner-Ivey B, Manevich Y, Schulte J, et al. Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer. Oncogene. 2013;32(45):5302–5314. doi:10.1038/onc.2012.62423334324
   PubMed Web of Science ®Google Scholar
• Wang R, Liu Y, Liu L, et al. Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression. EBioMedicine. 2019;40:118–134. doi:10.1016/j.ebiom.2019.01.04530711520
   PubMed Web of Science ®Google Scholar
• Kalinina EV, Berezov TT, Shtil AA, et al. Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med. 2012;153(6):878–881. doi:10.1007/s10517-012-1849-723113308
   PubMed Web of Science ®Google Scholar
• Cao J, Schulte J, Knight A, et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 2009;28(10):1505–1517. doi:10.1038/emboj.2009.10119369943
   PubMed Web of Science ®Google Scholar
• Guo QJ, Mills JN, Bandurraga SG, et al. MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer. Breast Cancer Res. 2013;15(4):R70. doi:10.1186/bcr346423971998
   PubMedGoogle Scholar
• Kurono S, Kaneko Y, Matsuura N, et al. Identification of potential breast cancer markers in nipple discharge by protein profile analysis using two-dimensional nano-liquid chromatography/nanoelectrospray ionization-mass spectrometry. Proteomics Clin Appl. 2016;10(5):605–613. doi:10.1002/prca.v10.526970563
   PubMed Web of Science ®Google Scholar
• Lacombe J, Mange A, Bougnoux AC, Prassas I, Solassol J. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1834–1842. doi:10.1158/1055-9965.EPI-14-026724957886
   PubMed Web of Science ®Google Scholar
• Stresing V, Baltziskueta E, Rubio N, et al. Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene. 2013;32(6):724–735. doi:10.1038/onc.2012.9322430214
   PubMed Web of Science ®Google Scholar
• Pendharkar N, Gajbhiye A, Taunk K, et al. Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers. J Proteomics. 2016;132:112–130. doi:10.1016/j.jprot.2015.11.02426642762
   PubMed Web of Science ®Google Scholar
• Karihtala P, Kauppila S, Soini Y, Arja Jukkola V. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer. 2011;11:262. doi:10.1186/1471-2407-11-26221693047
   PubMed Web of Science ®Google Scholar
• Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, Bay BH. Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol. 2010;36(2):359–364.20043069
   PubMed Web of Science ®Google Scholar
• Liu X, Feng R, Du L. The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett. 2010;584(14):3185–3192. doi:10.1016/j.febslet.2010.06.00220541551
   PubMed Web of Science ®Google Scholar
• Castellana B, Escuin D, Perez-Olabarria M, et al. Genetic up-regulation and overexpression of PLEKHA7 differentiates invasive lobular carcinomas from invasive ductal carcinomas. Hum Pathol. 2012;43(11):1902–1909. doi:10.1016/j.humpath.2012.01.01722542108
   PubMed Web of Science ®Google Scholar
• Tiedemann K, Sadvakassova G, Mikolajewicz N, et al. Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl Oncol. 2019;12(3):462–474. doi:10.1016/j.tranon.2018.11.01430583289
   PubMed Web of Science ®Google Scholar
• Byun JM, Kim SS, Kim KT, et al. Overexpression of peroxiredoxin-3 and −5 is a potential biomarker for prognosis in endometrial cancer. Oncol Lett. 2018;15(4):5111–5118. doi:10.3892/ol.2018.790929541251
   PubMed Web of Science ®Google Scholar
• Ahn HM, Yoo JW, Lee S, Lee HJ, Lee HS, Lee DS. Peroxiredoxin 5 promotes the epithelial-mesenchymal transition in colon cancer. Biochem Biophys Res Commun. 2017;487(3):580–586. doi:10.1016/j.bbrc.2017.04.09428431931
   PubMed Web of Science ®Google Scholar
• Kim B, Kim YS, Ahn HM, et al. Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer. Int J Oncol. 2017;51(1):298–306. doi:10.3892/ijo.2017.401328535004
   PubMed Web of Science ®Google Scholar
• Goncalves K, Sullivan K, Phelan S. Differential expression and function of peroxiredoxin 1 and peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast epithelial cells. Cancer Invest. 2012;30(1):38–47. doi:10.3109/07357907.2011.62938222236188
   PubMed Web of Science ®Google Scholar
• Seibold P, Hall P, Schoof N, et al. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients–potential differential effects by radiotherapy? Breast. 2013;22(5):817–823. doi:10.1016/j.breast.2013.02.00823489758
   PubMed Web of Science ®Google Scholar
• Chen L, Na R, Ran Q. Enhanced defense against mitochondrial hydrogen peroxide attenuates age-associated cognition decline. Neurobiol Aging. 2014;35(11):2552–2561. doi:10.1016/j.neurobiolaging.2014.05.00724906890
   PubMed Web of Science ®Google Scholar
• Mishra M, Jiang H, Wu L, Chawsheen HA, Wei Q. The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development. Cancer Lett. 2015;366(2):150–159. doi:10.1016/j.canlet.2015.07.00226170166
   PubMed Web of Science ®Google Scholar
• Shadel GS, Horvath TL. Mitochondrial ROS signaling in organismal homeostasis. Cell. 2015;163(3):560–569. doi:10.1016/j.cell.2015.10.00126496603
   PubMed Web of Science ®Google Scholar